Patients in the low SHR group showed significantly reduced event‐free survival and higher incidence rates of both primary endpoints compared with those in the high SHR group; (ii) rates of cardiovascular and all‐cause death were numerically higher in the low SHR group, although these differences did not reach statistical significance; and (iii) the association between low SHR and the risk of thromboembolic events and MACE was consistent across all clinical subgroups, with particularly pronounced associations observed in patients aged ≥65 years, males, those with diabetes, and individuals without a history of stroke/TIA/thromboembolism, or established vascular disease.
← all excerpts
Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort.
1
—
—